作者
Anthony C Nichols, Julie Theurer, Eitan Prisman, Nancy Read, Eric Berthelet, Eric Tran, Kevin Fung, John R de Almeida, Andrew Bayley, David P Goldstein, Michael Hier, Khalil Sultanem, Keith Richardson, Alex Mlynarek, Suren Krishnan, Hien Le, John Yoo, S Danielle MacNeil, Eric Winquist, J Alex Hammond, Varagur Venkatesan, Sara Kuruvilla, Andrew Warner, Sylvia Mitchell, Jeff Chen, Martin Corsten, Stephanie Johnson-Obaseki, Libni Eapen, Michael Odell, Christina Parker, Bret Wehrli, Keith Kwan, David A Palma
发表日期
2019/10/1
期刊
The Lancet Oncology
卷号
20
期号
10
页码范围
1349-1359
出版商
Elsevier
简介
Background
Transoral robotic surgery (TORS) with concurrent neck dissection has supplanted radiotherapy in the USA as the most common treatment for oropharyngeal squamous cell carcinoma (OPSCC), yet no randomised trials have compared these modalities. We aimed to evaluate differences in quality of life (QOL) 1 year after treatment.
Methods
The ORATOR trial was an investigator-initiated, multicentre, international, open-label, parallel-group, phase 2, randomised study. Patients were enrolled at six hospitals in Canada and Australia. We randomly assigned (1:1) patients aged 18 years or older, with Eastern Cooperative Oncology Group scores of 0–2, and with T1–T2, N0–2 (≤4 cm) OPSCC tumour types to radiotherapy (70 Gy, with chemotherapy if N1–2) or TORS plus neck dissection (with or without adjuvant chemoradiotherapy, based on pathology). Following stratification by p16 status, patients were …
学术搜索中的文章
AC Nichols, J Theurer, E Prisman, N Read, E Berthelet… - The Lancet Oncology, 2019